Syntara Limited Q4 2026 Earnings Call Transcript

Syntara Limited held its Q4 2026 earnings call on July 27, 2026, led by CEO Gary Phillips. The call covered the company's Appendix 4C quarterly report for June 2026 and recent announcements regarding SNT-4728 and the amsulostat programs for skin scarring and myelodysplastic syndrome. Phillips highlighted positive FDA feedback on the clinical development pathway for amsulostat in myelofibrosis, following the presentation of full program data to the agency. The company assembled a team of advisors for the FDA meeting. The call included a presentation followed by a Q&A session with investors.

First published Aug 4, 03:00 PM UTCUpdated Jul 28, 03:08 AM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 28, 03:08 AM UTCEditorial record as of Aug 4, 03:00 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

Opened from WirecurrentJul 28, 03:08 AM UTC

Syntara Limited Q4 2026 Earnings Call Transcript

Coverage sources

External reporting used to assemble this Story.

Syntara Limited Q4 2026 Earnings Call TranscriptAll Articles on Seeking AlphaNeutral / independentJul 28, 03:08 AM UTC

Follow the context

FDA